Tonix Pharmaceuticals (TNXP) Stock: Buy, Sell, or Hold?
TNXP - Tonix Pharmaceuticals Holding Corp.
$8.91
-0.32 (-3.47%)
▼
5d:
-9.63%
30d:
-33.41%
90d:
-29.9%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 09, 2026
Get Alerted When TNXP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: TNXP shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: TNXP shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: TNXP is currently trading at $8.91, which is considered oversold relative to its 30-day fair value range of $10.10 to $13.37.
Technical Outlook: Technically, TNXP is in a downtrend. The price is currently testing key support at $8.69. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $44.50 (+399.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TNXP is in a downtrend. The price is currently testing key support at $8.69. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $44.50 (+399.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$10.10 -
$13.37
Company Quality Score
50/100
(HOLD)
Options IV Signal
62th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
75.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 62th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.5%)
- BULLISH: Trading 399.4% below Wall St target ($44.50)
- WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$10.10 -
$13.37
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$1.74
(19.5%)
Support & Resistance Levels
Support Level
$8.69
Resistance Level
$11.19
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.13
Wall Street Target
$44.50
(+399.4%)
Revenue Growth (YoY)
577.9%
Share & Embed Analysis
Last updated: October 03, 2026 7:02 PM ET
Data refreshes hourly during market hours. Next update: 8:02 PM
Data refreshes hourly during market hours. Next update: 8:02 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TNXP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 49 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$570 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$310 | 66 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$63 | 60 BUY |
